Acurx Pharmaceuticals
ACXP
12 hedge funds and large institutions have $1.43M invested in Acurx Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 9 → 12 (+3)
25% more capital invested
Capital invested by funds: $1.15M → $1.43M (+$281K)
0.01% more ownership
Funds ownership: 0.17% → 0.18% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$37K |
| 2 |
SFA
Semmax Financial Advisors
Winston Salem,
North Carolina
|
+$15.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.25K |
| 2 |
BlackRock
New York
|
-$2.42K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DAM
1
Draper Asset Management
Smithtown,
New York
| $1.01M | – | – | – |
|
|
TWC
2
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $110K | – | – | – |
|
|
3
BlackRock
New York
| $61K | -$2.42K | -36 | -4% |
|
|
CWM
4
Castle Wealth Management
West Palm Beach,
Florida
| $49K | +$43.8K | +650 | New |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $43K | +$2.02K | +30 | +5% |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $42K | +$37K | +550 | New |
|
|
TAM
7
Tocqueville Asset Management
New York
| $38K | – | – | – |
|
|
PFGIA
8
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| $37K | – | – | – |
|
|
SFA
9
Semmax Financial Advisors
Winston Salem,
North Carolina
| $28K | +$15.6K | +231 | +367% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $7K | -$5.25K | -78 | -47% |
|
|
11
UBS Group
Zurich,
Switzerland
| $4K | +$3.5K | +52 | New |
|
ACXP Hedge Fund Activity: Q2 2022 in Review
12 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q2 2022, worth a combined $1.43M — up 25% from $1.15M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ACXP positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Osaic Holdings, opening a new position worth an estimated $37K. The largest seller was Tower Research Capital (TRC), cutting an estimated $5.25K.
- 12 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q2 2022, up from 9 in Q1 2022.
- Funds reported $1.43M of Acurx Pharmaceuticals stock for Q2 2022, up 25% quarter-over-quarter.
- 3 funds opened new Acurx Pharmaceuticals positions in Q2 2022 and 0 closed out, a net change of +3 holders.
- The largest Acurx Pharmaceuticals buyer in Q2 2022 was Osaic Holdings, an estimated $37K added.
- The largest Acurx Pharmaceuticals seller in Q2 2022 was Tower Research Capital (TRC), an estimated $5.25K sold.
Based on aggregated 13F filings for Q2 2022.